Suppr超能文献

二磷酸腺苷(ADP)诱导血小板活化的分子基础。II. P2Y1受体介导ADP诱导的血小板细胞内钙动员和形态变化。

Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets.

作者信息

Jin J, Daniel J L, Kunapuli S P

机构信息

Department of Physiology, Temple University Medical School, Philadelphia, Pennsylvania 19140, USA.

出版信息

J Biol Chem. 1998 Jan 23;273(4):2030-4. doi: 10.1074/jbc.273.4.2030.

Abstract

ADP is an important platelet agonist causing shape change from smooth discoid shape to spiculated spheres and platelet aggregation. However, the molecular mechanisms involved in ADP-induced platelet activation have not been elucidated. We demonstrated earlier the existence of two distinct ADP receptors on platelets, one coupled to phospholipase C, P2TPLC, and the other to inhibition of adenylyl cyclase, P2TAC (Daniel, J. L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J. B., and Kunapuli, S. P. (1998) J. Biol. Chem. 273, 2024-2029), in addition to the previously described P2X1 receptor. Here we report the cloning of a cDNA clone encoding the P2Y1 receptor from a human platelet cDNA library by homology screening with radiolabeled P2Y1-P2Y6 receptor cDNAs. ADP or 2-methyl(thio)-ADP-induced intracellular calcium increases were inhibited by the P2Y1 receptor-specific antagonists, adenosine 3'-phosphate 5'-phosphosulfate (A3P5PS), adenosine 3'-phosphate 5'-phosphate (A3P5P), and adenosine 2'-phosphate 5'-phosphate (A2P5P), in a concentration-dependent manner, but not by ARL 66096 or alpha, beta-MeATP. A3P5PS, A3P5P, and A2P5P also inhibited the shape change of aspirinated platelets induced by 10 microM ADP or 3 microM 2-methyl-(thio)-ADP in a concentration-dependent manner, with complete inhibition occurring at 300 microM. On the other hand ARL 66096 (100 nM), a potent P2TAC antagonist and alpha, beta-methylene-ATP (40 microM), a P2X1 receptor agonist, had no effect on ADP-induced platelet shape change. On the contrary, ADP-induced inhibition of adenylyl cyclase was blocked by ARL 66096, but not by alpha, beta-MeATP or the P2Y1 receptor-specific antagonists, A3P5PS, A3P5P, or A2P5P. These results demonstrate the role of the P2Y1 receptor in ADP-induced platelet shape change and calcium mobilization and support the idea that several P2 receptors are involved in the regulation of different aspects of platelet stimulus-response coupling.

摘要

二磷酸腺苷(ADP)是一种重要的血小板激动剂,可使血小板形状从光滑的盘状变为有刺的球状,并导致血小板聚集。然而,ADP诱导血小板激活所涉及的分子机制尚未阐明。我们之前已证明血小板上存在两种不同的ADP受体,一种与磷脂酶C偶联,即P2TPLC,另一种与腺苷酸环化酶的抑制作用偶联,即P2TAC(丹尼尔,J.L.,丹格尔迈尔,C.,金,J.,阿什比,B.,史密斯,J.B.,和库纳普利,S.P.(1998年)《生物化学杂志》273卷,2024 - 2029页),此外还有先前描述的P2X1受体。在此,我们报告通过用放射性标记的P2Y1 - P2Y6受体cDNA进行同源筛选,从人血小板cDNA文库中克隆出编码P2Y1受体的cDNA克隆。二磷酸腺苷(ADP)或2 - 甲基(硫代)- ADP诱导的细胞内钙增加受到P2Y1受体特异性拮抗剂3'-磷酸腺苷5'-磷酸硫酸酯(A3P5PS)、3'-磷酸腺苷5'-磷酸酯(A3P5P)和2'-磷酸腺苷5'-磷酸酯(A2P5P)的浓度依赖性抑制,但不受ARL 66096或α,β - 甲基ATP抑制。A3P5PS、A3P5P和A2P5P也以浓度依赖性方式抑制10微摩尔ADP或3微摩尔2 - 甲基 - (硫代)- ADP诱导的富血小板血浆中血小板的形状变化,在300微摩尔时完全抑制。另一方面,强效的P2TAC拮抗剂ARL 66096(100纳摩尔)和P2X1受体激动剂α,β - 亚甲基 - ATP(40微摩尔)对ADP诱导的血小板形状变化无影响。相反,ADP诱导的腺苷酸环化酶抑制被ARL 66096阻断,但不受α,β - 甲基ATP或P2Y1受体特异性拮抗剂A3P5PS、A3P5P或A2P5P阻断。这些结果证明了P2Y1受体在ADP诱导的血小板形状变化和钙动员中的作用,并支持了几种P2受体参与血小板刺激 - 反应偶联不同方面调节的观点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验